Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,189.41
-44.2500-3.59%
Post-market: 1,189.610.1970+0.02%19:59 EDT
Volume:3.01M
Turnover:3.60B
Market Cap:1.12T
PE:39.93
High:1,235.78
Open:1,234.00
Low:1,180.01
Close:1,233.66
52wk High:1,292.65
52wk Low:712.05
Shares:945.38M
Float Shares:939.00M
Volume Ratio:1.12
T/O Rate:0.32%
Dividend:6.69
Dividend Rate:0.56%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:33.19
PE(LYR):51.83

Loading ...

Sector Update: Healthcare

MT Newswires Live
·
Aug 25

Eli Lilly’s New Obesity Drug LY3549492 Moves Forward With Completed Phase 1 Trial

TIPRANKS
·
Aug 25

Eli Lilly (LLY) On Foundayo Launch And Higher Outlook Faces A Rich Valuation

Simply Wall St.
·
Aug 24

Roche, Eli Lilly's Alzheimer's Blood Test Gets FDA Clearance

Reuters
·
Aug 24

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Aug 24

Eli Lilly: Working with Nice on Assessment of Foundayo for Potential Use on Nhs in England

THOMSON REUTERS
·
Aug 24

Eli Lilly Launches Oral Weight-Loss Pill Foundayo in UK

Reuters
·
Aug 24

Eli Lilly: Foundayo NOW Available in UK to be Prescribed for Eligible Adults Via Private Prescription

THOMSON REUTERS
·
Aug 24

Eli Lilly: in UK, Foundayo is Priced Lower than Mounjaro; Likely to be in Order of £100 to £120

THOMSON REUTERS
·
Aug 24

Eli Lilly Targets Ramadan Diabetes Market With New Orforglipron Trial

TIPRANKS
·
Aug 22

Eli Lilly’s Dulaglutide Study Sheds Light on Fasting Risks and Diabetes Care

TIPRANKS
·
Aug 22

Pharma Stocks Have Rallied. 2 Stocks to Avoid-and 2 to Buy.

Dow Jones
·
Aug 21

Eli Lilly Advances Early-Stage Eloralintide Trial: What Investors Should Watch

TIPRANKS
·
Aug 21

Eli Lilly’s Lebrikizumab Trial Completion Signals New Growth Path in Atopic Dermatitis

TIPRANKS
·
Aug 21

Eli Lilly Revenue Jumps 48% as Mounjaro and Zepbound Sales Reach $14.9B

TradingKey
·
Aug 20

Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines

Reuters
·
Aug 20

7 Growth Stocks Holding up in a Tough Market

Dow Jones
·
Aug 20

Will Foundayo’s UK GLP‑1 Approval and New R&D Deals Change Eli Lilly's (LLY) Narrative?

Simply Wall St.
·
Aug 20

Amplitude Therapeutics: Lilly to GET Exclusive, Target-Specific Rights to Develop ,Commercialize Licensed Products Directed to Collaboration Targets

THOMSON REUTERS
·
Aug 20

Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying Rna Vaccines for Infectious Diseases

THOMSON REUTERS
·
Aug 20